首页/数据集/EMERALD TRIAL Table S1. Statistical Analyses

EMERALD TRIAL Table S1. Statistical Analyses

NIAID Data Ecosystem2026-05-10 收录

临床试验统计分析

数据链接：

https://figshare.com/articles/dataset/EMERALD_TRIAL_Table_S1_Statistical_Analyses/30916808 数据链接链接失效反馈

官方服务：

资源简介：

Statistical analyses for primary, secondary and exploratory outcomes of EMERALD trial.

应用场景：

创建时间：

2025-12-22

临床试验统计分析

干预效果评估

AAF: standard amino acid formula; AAF-syn: amino acid formula with synbiotic blend. Number of samples: AAF – OM: 16, AAF – 6M: 16, AAF-12M: 16, AAF-syn – 0M: 23, AAF-syn – 6M: 23, AAF-syn – 12M: 22. (

Figshare2025-09-10 更新50

Analysis of covariance (ANCOVA)* of the difference between the rituximab versus control groups in the distributions of AUC mean values at 12 months of follow-up without and with transformations adjusted for age and sex and the baseline value.

临床试验统计分析

药物疗效评估

*In each analysis, the like-transformed (or untransformed) baseline AUC mean value was employed as an adjusting covariate, e.g. of the baseline value in the analysis of the 12 month values. The means

Figshare2015-12-02 更新40

mITT and Per protocol analysis at end of treatment.

临床试验统计分析

药效评估

mITT and Per protocol analysis at end of treatment.

NIAID Data Ecosystem30

Results for the two primary outcomes per protocol and intention-to-treat analysis.

临床试验统计分析

Results for the two primary outcomes per protocol and intention-to-treat analysis.

NIAID Data Ecosystem40

Additional file 2 of Assessing non-inferiority for binary matched-pairs data with missing values: a powerful and flexible GEE approach based on the risk difference

非劣效性试验